A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Solid TumorsAdvanced Solid TumorsMetastatic Solid Tumors
- Interventions
- Registration Number
- NCT05836324
- Lead Sponsor
- Incyte Corporation
- Brief Summary
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 408
- ≥18 years old
- Histologically or cytologically confirmed advanced or metastatic malignancies as defined in the protocol.
- Part 1: Participants must have experienced disease progression after treatment with, be intolerant to, or be ineligible for, or refused available therapies, including anti-PD-(L)1 or anti-CTLA4 therapy if applicable, that are known to confer clinical benefit. Part 2: depending on cohort, participants may have received or not prior treatment for the malignancy under study.
- ECOG performance status score of 0 or 1.
- Willingness to undergo pre- and on-treatment tumor biopsy (core or excisional). Biopsies are mandatory depending on the cohorts.
- Presence of measurable disease according to RECIST v1.1.
-
Any known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years.
-
Not recovered to ≤ Grade 1 or baseline from residual toxicities of prior therapy.
-
Has active autoimmune disease requiring systemic immunosuppression with corticosteroids.
-
Brain or CNS metastases untreated or that have progressed.
-
History of organ transplant, including allogeneic stem cell transplantation.
-
History of clinically significant or uncontrolled cardiac disease.
-
Active HBV, active HCV, or HIV positive.
-
Is on chronic systemic steroids (> 10 mg/day of prednisone or equivalent).
-
Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment
-
Participants that have been initiated on or had modifications in anticoagulation therapies within the last 3 months prior to first dose of treatment.
-
Significant concurrent, uncontrolled medical condition, eg:
- Cardiovascular: Participants with known vasculitis, aneurisms, and other vascular malformations of clinical significance or history of myocarditis.
- Gastrointestinal: Any bowel obstruction within 60 days prior to C1D1.
-
Participants with adequate laboratory values within the protocol defined ranges.
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Part 1a - Dose Escalation Monotherapy INCA33890 INCA33890 will be administered at the protocol-defined dose based on cohort assignment. Part 1b-Dose Expansion Monotherapy INCA33890 INCA33890 will be administered at the protocol-defined dose based on cohort assignment. Part 2a - Dose Escalation Combination Therapy - Group 1 bevacizumab INCA33890 will be administered in combination with bevacizumab at the protocol-defined dose based on cohort assignment. Part 2a - Dose Escalation Combination Therapy - Group 1 INCA33890 INCA33890 will be administered in combination with bevacizumab at the protocol-defined dose based on cohort assignment. Part 2a - Dose Escalation Combination Therapy - Group 2 INCA33890 INCA33890 will be administered in combination with bevacizumab and FOLFIRI at the protocol-defined dose based on cohort assignment. Part 2a - Dose Escalation Combination Therapy - Group 2 bevacizumab INCA33890 will be administered in combination with bevacizumab and FOLFIRI at the protocol-defined dose based on cohort assignment. Part 2a - Dose Escalation Combination Therapy - Group 2 FOLFIRI INCA33890 will be administered in combination with bevacizumab and FOLFIRI at the protocol-defined dose based on cohort assignment. Part 2a - Dose Escalation Combination Therapy - Group 3 INCA33890 INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose based on cohort assignment. Part 2a - Dose Escalation Combination Therapy - Group 3 bevacizumab INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose based on cohort assignment. Part 2a - Dose Escalation Combination Therapy - Group 3 FOLFOX INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose based on cohort assignment. Part 2b - Dose Expansion Combination Therapy - Group 2 bevacizumab INCA33890 will be administered in combination with bevacizumab and FOLFIRI at the protocol-defined dose based on cohort assignment. Part 2a - Dose Escalation Combination Therapy - Group 4 INCA33890 INCA33890 will be administered in combination with cetuximab at the protocol-defined dose based on cohort assignment. Part 2b - Dose Expansion Combination Therapy - Group 1 bevacizumab INCA33890 will be administered in combination with bevacizumab at the protocol-defined dose based on cohort assignment. Part 2b - Dose Expansion Combination Therapy - Group 3 bevacizumab INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose based on cohort assignment. Part 2b - Dose Expansion Combination Therapy - Group 4 INCA33890 INCA33890 will be administered in combination with cetuximab at the protocol-defined dose based on cohort assignment. Part 2a - Dose Escalation Combination Therapy - Group 4 Cetuximab INCA33890 will be administered in combination with cetuximab at the protocol-defined dose based on cohort assignment. Part 2b - Dose Expansion Combination Therapy - Group 2 FOLFIRI INCA33890 will be administered in combination with bevacizumab and FOLFIRI at the protocol-defined dose based on cohort assignment. Part 2b - Dose Expansion Combination Therapy - Group 1 INCA33890 INCA33890 will be administered in combination with bevacizumab at the protocol-defined dose based on cohort assignment. Part 2b - Dose Expansion Combination Therapy - Group 2 INCA33890 INCA33890 will be administered in combination with bevacizumab and FOLFIRI at the protocol-defined dose based on cohort assignment. Part 2b - Dose Expansion Combination Therapy - Group 3 INCA33890 INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose based on cohort assignment. Part 2b - Dose Expansion Combination Therapy - Group 3 FOLFOX INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose based on cohort assignment. Part 2b - Dose Expansion Combination Therapy - Group 4 Cetuximab INCA33890 will be administered in combination with cetuximab at the protocol-defined dose based on cohort assignment.
- Primary Outcome Measures
Name Time Method Treatment Emerging Adverse Events (TEAEs) Up to 2 years TEAEs leading to dose modification or discontinuation Up to 2 years Dose Limiting Toxicities (DLTs) Up to 28 days
- Secondary Outcome Measures
Name Time Method Objective response Rate 2 years Disease Control Rate 2 years Duration of Response 2 years Pharmacokinetics Parameter : Cmax of INCA33890 Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up Pharmacokinetics Parameter : AUC(0-t) of INCA33890 Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up Pharmacokinetics Parameter : AUC 0-∞ of INCA33890 Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up Pharmacokinetics Parameter : Tmax of INCA33890 Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up Pharmacokinetics Parameter : Cmin of INCA33890 Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up Pharmacokinetics Parameter : CL of INCA33890 Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up Pharmacokinetics Parameter : Vz of INCA33890 Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up Pharmacokinetics Parameter : t1/2 of INCA33890 Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (36)
The Angeles Clinic and Research Institute
🇺🇸Los Angeles, California, United States
Valkyrie Clinical Trials
🇺🇸Los Angeles, California, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Cancer and Hematology Centers of Western Michigan-Start Midwest
🇺🇸Grand Rapids, Michigan, United States
Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
Nyu Langone Health - Long Island Hospital
🇺🇸Mineola, New York, United States
Laura and Isaac Perlmutter Cancer Center
🇺🇸New York, New York, United States
University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Lifespan Cancer Research Institute
🇺🇸Providence, Rhode Island, United States
University of Texas Md Anderson Cancer Center
🇺🇸Houston, Texas, United States
Scroll for more (26 remaining)The Angeles Clinic and Research Institute🇺🇸Los Angeles, California, United States